| 000 | 01857 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518005346.0 | ||
| 264 | 0 | _c20190131 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1613-2246 | ||
| 024 | 7 |
_a10.1007/s10384-018-0636-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNakai, Shunichiro | |
| 245 | 0 | 0 |
_aThe 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. _h[electronic resource] |
| 260 |
_bJapanese journal of ophthalmology _cJan 2019 |
||
| 300 |
_a100-108 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aChoroid _xblood supply |
| 650 | 0 | 4 |
_aChoroid Diseases _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aFundus Oculi |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPhotochemotherapy _xmethods |
| 650 | 0 | 4 |
_aPhotosensitizing Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aPolyps _xdrug therapy |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xadministration & dosage |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVerteporfin _xtherapeutic use |
| 650 | 0 | 4 | _aVisual Acuity |
| 700 | 1 | _aMatsumiya, Wataru | |
| 700 | 1 | _aKeiko, Otsuka | |
| 700 | 1 | _aMiki, Akiko | |
| 700 | 1 | _aNakamura, Makoto | |
| 700 | 1 | _aHonda, Shigeru | |
| 773 | 0 |
_tJapanese journal of ophthalmology _gvol. 63 _gno. 1 _gp. 100-108 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10384-018-0636-z _zAvailable from publisher's website |
| 999 |
_c29022400 _d29022400 |
||